MMR, Varicella vacc (control)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

MeaslesMumpsRubellaVaricella

Phase 2

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

CompletedNCT00352898

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2006-04-30End: 2006-11-30Updated: 2016-10-07

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

CompletedNCT00353288

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2006-03-31End: 2006-11-30Updated: 2016-10-07

Related Papers

Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.

2008-11-1122 citations